Xbrane Biopharma Q4 2024: Eventful times - Redeye

Redeye provides an updated view on Xbrane following its year-end report, which showed continued growth in end-customer sales and signs of improving financials. However, increasing uncertainty in the ranibizumab market leads us to lower our fair value range.

Länk till analysen i sin helhet: https://www.redeye.se/research/1082297/xbrane-biopharma-q4-2024-eventful-times?utm_source=finwire&utm_medium=RSS